“Comment ROSACEA and I'll send you the simple pattern guide. Rosacea skin does not need to win a toughness contest. A few hills I will die on: more exfoliation is not automatically better, redness plus bumps is not always ordinary acne, and mostly flushing/visible redness can need a different approach from persistent inflammatory bumps.”

On proposition 3 (different presentations, different approaches), the evidence is the strongest of the three. The ROSCO panel reached consensus on initial, combination and maintenance therapy using a phenotype-led approach to treating cutaneous rosacea features, developed into a first-line therapy algorithm, and recent trials specifically addressing a single feature rather than a subtype prompted this shift toward treating rosacea according to its phenotypes rather than subtypes. The 2019 ROSCO update further refines and extends recommendations for a phenotype approach in rosacea diagnosis, classification and management. The specific treatments diverge by feature: topical brimonidine and oxymetazoline are recommended for persistent erythema, while topical azelaic acid, ivermectin, metronidazole, minocycline and oral doxycycline, tetracycline and isotretinoin are recommended for papules and pustules, with vascular lasers and light devices for telangiectases. Critically, the divergence is not merely administrative. Topical metronidazole, topical azelaic acid, and oral doxycycline reduce erythema related to vascular inflammation but have negligible effects on background erythema caused by permanently dilated superficial vessels. An older review describes the same split along subtype lines: for the erythematotelangiectatic form, topical treatments include metronidazole, azelaic acid, and brimonidine, with laser therapies also beneficial, while for the papulopustular form a combination of topical therapies and oral antibiotics is considered. The NHS-aligned local guideline reflects the same split in practice, listing brimonidine 0.5% gel applied topically once daily on an as-needed basis for temporary relief of persistent erythema under the erythematotelangiectatic heading, separately from the ivermectin and azelaic acid pathway for papulopustular disease. On proposition 2 (redness plus bumps is not always acne), the differential-diagnosis literature is explicit. Comedones are a pathognomonic feature of acne and help differentiate it from other conditions in the differential diagnosis, such as rosacea, periorificial dermatitis, and Malassezia (Pityrosporum) folliculitis. Papulopustular rosacea is characterized by persistent central facial erythema and transient crops of papules and/or pustules in the center of the face; the papulopustular subtype resembles acne vulgaris, but comedones are absent. The NICE-aligned primary care summary lists the recognition criteria as persistent central facial erythema with or without flushing, papules and pustules without comedones, and telangiectasia, with ocular symptoms possible. Other conditions also enter the differential: one case report notes that for facial papulopustular eruptions the differential diagnoses include folliculitis, furuncles, demodex folliculitis, acne vulgaris, and papulopustular rosacea. On proposition 1 (more exfoliation is not automatically better), the support is guideline and consensus level rather than trial level, but it is direct and from authoritative bodies. The AAD advises that anything that irritates your skin can cause rosacea to flare, and recommends using fingertips to gently wash and rinse the face without a washcloth or facial sponge, and avoiding rubbing, scrubbing, or massaging skin with rosacea. The National Rosacea Society states that heavy rubbing, scrubbing, exfoliation, or other rough application of products will just inflame your skin, and reports survey findings in which patients cited alcohol (66%), witch hazel (30%), fragrance (30%), menthol (21%), peppermint (14%) and eucalyptus oil (13%) as irritation triggers, and most respondents said they avoided astringents and exfoliating agents. Secondary consumer-health sources echo this and cite supporting data: one study reportedly found 82% of rosacea patients had irritable skin with burning or stinging when using cosmetic products, especially those most likely to interfere with the skin barrier such as exfoliants, soaps, and tonics. On the speaker: the account is operated by Lindsey Zubritsky, MD, FAAD, whose Instagram bio identifies her as a board certified dermatologist and states that no content is medical advice.